Clinical Trials Browser

INDUSTRY × Lymphoma × Antibodies, Bispecific × Clear all

NCT05293912 2025-03-18

SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Lymphoma, Hematologic Neoplasms